Clinical Immuno-Oncology

Offering focused, practical, and up-to-date content on immunotherapies used to treat a wide variety of cancer types, "Clinical Immuno-Oncology" covers the basic cellular and molecular mechanisms...

Lire la suite keyboard_arrow_right

Auteur(s) John E. Niederhuber
Date 16/06/2023
Pages 400
Taille 0 X 0
Type Relié
ISBN 9780323877633

Description détaillée : Clinical Immuno-Oncology

Offering focused, practical, and up-to-date content on immunotherapies used to treat a wide variety of cancer types, Clinical Immuno-Oncology covers the basic cellular and molecular mechanisms involved in cancer initiation and progression.

The text reviews the development of tumor specific antigens and the challenges of developing cancer immunotherapies. Every effort is made to relate the fundamental aspects of host immunity to the efficacy of current immunotherapies and how they work in conjunction with the immune system to combat cancer.

What is the content of "Clinical Immuno-Oncology" ?

This foundational resource explains the basics of cancer immunotherapy, discusses best practices, and provides recommendations from experienced clinicians in the field.

Dr. John E. Niederhuber and a team of expert contributing authors provide clinically focused information essential for integrating these new therapies into practice - making this an ideal resource for fellows, practitioners, and other cancer team members in medical oncology, radiation oncology, cancer surgery, immunology, and cancer research.

  • Offers balanced and synthesized content on clinical science, clinical and translational research, and evidence-based practice for cutting-edge immunotherapies.

  • Discusses clinical applications of immunotherapies in common types of cancer including melanoma, breast cancer, pancreatic cancer, colon and rectum cancer, prostate cancer, leukemias, and hematologic malignancies.

  • Includes dedicated chapters on immune responses, innate immunity, active immunization against cancer, and cell-based therapies by leading experts.

  • Covers key topics such as cancer immunotherapy in the presence of COVID-19, immunotherapeutics, new findings concerning the role of the microbiome in immunotherapy, advances in engineered cell-based therapies, and active immunization against cancer.

  • An eBook version is included with purchase. The eBook allows you to access all of the text, figures and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud.  


Who is the author of "Clinical Immuno-Oncology" ?

John E. Niederhuber : Adjunct Professor, Departments of Surgery and Oncology; Deputy Director, The Johns Hopkins Clinical Research Network, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Sommaire : Clinical Immuno-Oncology

Tentative TOC:


Chapter 1.0 Development and Structure of the Lymphoid System

embryologic development

gross anatomy of the human immune system

lymphatic endothelial cells, heterogeneity of, and lymph node microscopic structure

lymph node function; afferent lymph cellular components

role of the gut microbiome in immune system development

specific functions related to the spread of cancer

cancer-induced lymphangiogeneis; sentinel LNs

Chapter 2.0 The Chemistry, Structure, and Function of Immunoglobulins

immunoglobulin isotypes

the structure of immunoglobulins

the genetics of immunoglobulin diversity

antibody-dependent cellular cytotoxicity

heavy-chain C domain and role of glycosylation

the development of humanized monoclonals

Chapter 3.0 The Role of the Complement System in Cancer

complement system activation pathways (classical, alternative and lectin)

the role of complement activation in cancer progression

complement regulatory proteins (CRPs) and cancer

the role of compliment activation in the tumor microenvironment enhances tumor growth

complement-dependent cytotoxicity in immune therapy of cancer

formation of the membrane attack complex (MAC)

potential application of anti-complement cancer therapies (C3aR/C5aR/IL-10 pathway)

Chapter 4.0 Cancer as Non-Self

4.1 primary generator of tumor-specific transplantation type antigens

4.2 character of non-self, tumor associated antigens

4.3 immune surveillance ? innate immunity

4.4 distinguishing between self and non-self

4.5 toll-like receptors (TLRs); soluble bioactive proteins such as cytokines and C? proteins

4.6 NK cells

Chapter 5.0 The Adaptive Immune Response in Cancer

the diversity of active tumor antigen receptors

target specificity without limits in cancer-receptor variability

tumor antigen presentation; dendritic cells

immune response stimulation against the cancer

Cytotoxic T-cells and T-regulatory cells

B-cells and antibodies

Chapter 6.0 The Science of Innate Immunity

6.1 critical regulator of human inflammatory disease

6.2 anatomic and physiologic barriers to pathogens ? cancer causing viruses

6.3 centrally a limited number of critical receptors

6.4 the character of the inflammatory response

6.5 lack of ability to form memory

6.5 role in activating subsequent adaptive immune response

Chapter 7.0 Immune Surveillance

7.1 history of concept (Ilya Mechnikov 1908 Nobel Prize)

7.2 evidence for immune surveillance today

7.3 cancer in the immunocompromised host

Chapter 8.0 Cancer ? Avoiding Immune Detection

8.1 cancer and the presence of immune resistance

8.2 concept for the development of tumor cell tolerance

Chapter 9.0 Active Immunization Against Cancer and Cell-based Therapies

9.1 infusing in-vitro expanded Tumor Infiltrating Lymphocytes (TILs)

9.2 infusing dendritic cells pre-loaded with tumor specific oligopeptide antigens

9.3 B7 co-activating receptor

9.4 vaccines

Chapter 10.0 The Three Major Clinical Components of Cancer Immunotherapy

(modulating cell-mediated immune mechanisms)

10.1 the role of and application of check point blockade

10.2 the role and application of cell-based therapies including CAR-T cell therapies

10.3 antibodies (and vaccines); monoclonal antibodies and novel application of bi- or tri-specifics

Chapter 11.0 The Clinical Application of Immunotherapeutics

11.1 in melanoma cancer

11.2 in breast cancer

11.3 in pancreatic cancer

11.4 in colon and rectum cancer

11.5 in prostate cancer

11.6 in leukemias and hematologic malignancies

11.7 in other malignancies

Chapter 12.0 Cancer Immunotherapy in the Presence of COVID-19

12.1 immune response to coronavirus-2 infection

12.2 CD8+ T cell depression during chronic viral infection and cancer

12.3 checkpoint inhibitors in cancer patients with coronavirus infection

12.4 coronavirus depletion of CD4+ T cells

113,74 €

Sur commande

Expédition sous 6 à 10 jours

113,74 €

Bénéficiez de la remise de 5% en choisissant le retrait en magasin

Livraison à 0.01€ à partir de 35€

d'achats en France Métropolitaine

Satisfait ou remboursé

sous 14 jours ouvrés

Paiements sécurisés

3D Secure

Service client

Lundi au Vendredi : de 10h à 18h30
au 04 67 63 62 19 ou par email